

Session Title: #187: Lymphoma and Plasma Cell Disorders

Session Type: Poster Discussion Session

Date: Friday, June 4

Location: E450a

Time: 2:00 PM - 6:00 PM

- Lymphoma and Plasma Cell Disorders

Robert Z. Orlowski, MD, PhD

- Lymphoma and Plasma Cell Disorders

Nancy Bartlett, MD

1 #8022-Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.

Vaishali Santhorawala

2 #8023-Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.

Donna Ellen Reece

3 #8024-Use of melphalan (M)/dexamethasone (D)/bortezomib in AL-amyloidosis.

Cristina Gasparetto

4 #8025-A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.

Angela Dispenzieri

5 #8026-Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis.

Daniel J. Landsburg

- Discussion: New developments in amyloidosis

Giampaolo Merlini, MD, PhD

6 #8027-Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene *PSMD4*.

John D. Shaughnessy

7 #8028^ -Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.

Douglas E Joshua

8 #8029-Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).

William Bensinger

9 #8030^ -Phase I study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

Maria-Victoria Mateos

10 #8031-Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

Paul Gerard Guy Richardson, MD

11 #8032-Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

Anuj Kumar Mahindra

- Discussion: Personalized therapy and new agents in myeloma

Robert Z. Orlowski, MD, PhD

12 #8033-Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study.

Stephanie A. Gregory

13 #8034-A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium Trial (AMC 047).

Alexandra M. Levine

14 #8035-HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.

Marcus Hentrich

- Discussion: Approaches for HIV associated lymphoma

Lawrence D. Kaplan, MD

15 #8036-Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.

Nathan Hale Fowler

16 #8037-Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003).

Craig B. Reeder

17 #8038-Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with non-germinal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).

Francisco J. Hernandez-Ilizaliturri

18 #8039-Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.

Sonali M. Smith

19 #8040-Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

Lee Schwartzberg

20 #8041-Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma.

Jeffrey L. Vacirca

21 #8042[^]-Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).

Myron Stefan Czuczman, MD

- Discussion: Novel agents in lymphoma

Nancy Bartlett, MD

22 #8043-Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).

Jonathan Laurence Berkowitz, MD, PhD

23 #8044-Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study.

Motoko Yamaguchi, MD, PhD

24 #8045-Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.

Francine M. Foss, MD

25 #8046-A phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas.

Deborah A. Mulford

Session Title: #67: Management of Older Patients with Lymphoma and Myeloma

Session Type: Education Session

Date: Friday, June 4

Location: E354b

Time: 3:30 PM - 4:45 PM

- Using the Geriatric Assessment and Related Strategies in the Practical Management of Lymphoma and Myeloma Patients.

Stuart M. Lichtman, MD

- Approaches to Diffuse Large Cell Lymphoma in the Very Elderly.

Vicki A. Morrison, MD

- New and Old: New Regimens for Older Multiple Myeloma Patients.

Jesús San-Miguel, MD, PhD

Session Title: #254: Lymphoma and Plasma Cell Disorders

Session Type: Poster Discussion Session

Date: Friday, June 4

Location: E354b

Time: 5:00 PM - 6:00 PM

- Lymphoma and Plasma Cell Disorders

Robert Z. Orlowski, MD, PhD

- Lymphoma and Plasma Cell Disorders

Nancy Bartlett, MD

1 #8022-Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): Analysis of a Southwest Oncology Group trial.

Vaishali Santhorawala

2 #8023-Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.

Donna Ellen Reece

3 #8024-Use of melphalan (M)/dexamethasone (D)/bortezomib in AL-amyloidosis.

Cristina Gasparetto

4 #8025-A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.

Angela Dispenzieri

- Discussion: New developments in amyloidosis

Giampaolo Merlini, MD, PhD

6 #8027-Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene *PSMD4*.

John D. Shaughnessy

7 #8028^ -Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.

Douglas E Joshua

8 #8029-Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).

William Bensinger

9 #8030^ -Phase I study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

Maria-Victoria Mateos

10 #8031-Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

Paul Gerard Guy Richardson, MD

11 #8032-Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

Anuj Kumar Mahindra

- Discussion: Personalized therapy and new agents in myeloma

Robert Z. Orlowski, MD, PhD

12 #8033-Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt's lymphoma (BL): Preliminary results of a multicenter phase II study.

Stephanie A. Gregory

13 #8034-A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium Trial (AMC 047).

Alexandra M. Levine

14 #8035-HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial.

Marcus Hentrich

- Discussion: Approaches for HIV associated lymphoma

Lawrence D. Kaplan, MD

15 #8036-Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.

Nathan Hale Fowler

16 #8037-Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003).

Craig B. Reeder

17 #8038-Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with non-germinal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R).

Francisco J. Hernandez-Ilizaliturri

18 #8039-Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: Final results of CALGB 50602.

Sonali M. Smith

19 #8040-Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

Lee Schwartzberg

20 #8041-Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma.

Jeffrey L. Vacirca

21 #8042-Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL).

Myron Stefan Czuczman, MD

- Discussion: Novel agents in lymphoma

Nancy Bartlett, MD

22 #8043-Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL).

Jonathan Laurence Berkowitz, MD, PhD

23 #8044-Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study.

Motoko Yamaguchi, MD, PhD

24 #8045-Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.

Francine M. Foss, MD

25 #8046-A phase I/II trial of clofarabine in patients with relapsed T-cell or NK-cell lymphomas.

Deborah A. Mulford

Session Title: #208: Lymphoma and Plasma Cell Disorders

Session Type: General Poster Session

Date: Saturday, June 5

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

22A #8047-Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL).

Ellen Kim

22B #8048-Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.

Barbara Pro

22C #8049-Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial-A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Bertrand Joly

22D #8050-Transcriptome adaptation caused by vorinostat/bexarotene combination therapy in advanced cutaneous T-cell lymphoma.

Maria B. Karpova

22E #8051-Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience.

Jenny Vu Pozadzides, MD

22F #8052-Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma.

Kein-Leong Yim

22G #8053-Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous t-cell lymphoma (CTCL).

David J. Straus, MD

22H #8054-Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival.

Andrei R. Shustov

23A #8055-Duration of response in three phase III studies of denileukin diftitox in cutaneous T-cell lymphoma (CTCL).

Madeleine Duvic

23B #8056-T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant.

Francesca Montanari

23C #8057-ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A ten-year follow-up study.

Nicolas Batty

23D #8058-Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)?

Andrea Gallamini

23E #8059-Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study.

David C. Hodgson

23F #8060-Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT.

Carmen Martinez

23G #8061-Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.

Martin Hutchings

23H #8062-Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

Nancy Bartlett, MD

24A #8063-Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD.

Ritesh Patil

24B #8064-Results of the SMARTE-r-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).

Michael Pfreundschuh

24C #8065-Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).

Kerri A Pierz

24D #8066-Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse.

Dhaval R. Mehta, MD

24E #8067-Frontline therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) lead to superior outcome in mantle cell lymphoma (MCL).

Tatyana Feldman

24F #8068-CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab.

Holbrook Edwin Kohrt

24G #8069-Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Corinne Haioun

24H #8070-Correlation of the intra-tumor phospholipid-related signatures determined noninvasively by phosphorus and hydrogen MR spectroscopy: An approach to increase the sensitivity and applicability of the technique to predict therapeutic outcome in non-Hodgkin's lymphoma.

Fernando Arias-Mendoza

25A #8071-Duration of remission using I-131 tositumomab in patients with B-cell lymphoma relapsing after autologous stem cell transplant.

David Douglas Shepard

25B #8072-Diffuse large b-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at m. d. anderson cancer center.

Guilherme F Perini

25F #8073-Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma (FL) treated with radiotherapy.

Puneet Bains

25G #8074-Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factors in 40 consecutive Asian patients.

Wai Meng David Tai

25H #8075-Immunochemotherapy with rituximab in combination with fludarabine and epirubicin as first-line treatment in patients with chronic lymphocytic leukemia.

Kai Uwe Chow

26A #8076-CpG oligodeoxynucleotides directly suppress the growth of aggressive human B-cell lymphomas.

Reiko E Yamada

26B #8077-Clinical characteristics of non-Hodgkin's Lymphoma (NHL) in Vietnam era (V) and non-Vietnam era veterans (Non V).

Shanthi Srinivas

26F #8078-Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL).

George Edward Manoukian, MD

26G #8079-Comparison of contrast-enhanced CT, PET/CT, PET, and low-dose non-contrast enhanced CT imaging of diffuse large B-cell (DLBCL), follicular (FL), small lymphocytic/CLL (CLL/SLL), and marginal zone lymphomas (MZL).

Elise A Chong

26H #8080-Association of serum B7-H1 level and lymphopenia in diffuse large B-cell non-Hodgkin lymphoma.

Ryan A. Wilcox

27A #8081-High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial.

Andrea Assanelli

27B #8082-Quality of life in 269 poor risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial.

Nicolas Mounier

27C #8083-Clinicopathological differences between EBV-positive and EBV-negative diffuse large B-cell lymphoma.

Brady Ernesto Beltran

27D #8084-Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma.

Ya jun Li

27E #8085-Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone and rituximab.

Nicole Aqui

27F #8086-Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety.

Robert E. Martell

27G #8087-Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies.

Keisuke Mitsuoka, PhD

27H #8088-Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance.

Carla Casulo, MD

28A #8089-Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).

Rute Alvarez

28B #8090-Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation.

Ling-Hua Zhang

28C #8091-Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents.

Jia Ruan

28D #8092-The association between the mantle cell lymphoma international prognostic index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).

Anthony R. Mato

28E #8093-Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase.

Peter Wojciech Szlosarek

28F #8094-Efficacy of combination of rituximab (R), obatoclox (O) and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL).

Wasif Riaz

28G #8095-Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.

Matthew John Barth, MD

28H #8096-Rituximab-related (R-R) reactivation of hepatitis B virus (HBV) in lymphoma: Analysis of FDA safety reports and a systematic literature review with meta-analysis.

Andrew M. Evens

29A #8097-Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).

Junji Suzumiya

29B #8098-Effect of a rituximab-based regimen on the incidence of CNS relapse in patients with diffuse large B-cell lymphoma.

Mervat Mahrous

29C #8099-Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.

Talia Pindyck

30A #8100-Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL).

Christopher Flowers

30B #8101-Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Shinae Kim

30C #8102-18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients.

Dominick Michael Lamonica

31A #8103-Maximum standardized uptake (SUVmax) on initial 18 FDG-PET/CT as prognostic value in patients with diffuse large B-cell lymphoma.

BoRan Kwon

31B #8104-Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).

David Belada

31C #8105-Radioimmunotherapy for consolidation and relapse therapy for aggressive B-cell non-Hodgkin lymphoma: Retrospective analysis of the International RIT-Network.

Karin Hohloch

32A #8106-A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.

Vicki A. Morrison, MD

32B #8107-Maintenance rituximab is associated with improved clinical outcome in rituximab-naïve patients with Waldenstrom's macroglobulinemia (WM) who respond to a rituximab-containing regimen.

Leukothea I Ioakimidis

32C #8108-Association of CR/VGPR with progression-free survival in rituximab-naïve WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in FcγRIIIA-158.

Zachary R Hunter

33A #8109-Long-term follow-up of patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia) who were treated with alemtuzumab.

Jacob D Soumerai

33B #8110-Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenstrom's macroglobulinemia, and effect on miRNA expression.

Douglas W McMillin

33C #8111-Association of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, with MGUS and multiple myeloma in different ethnic groups.

Sandra Grass

34A #8112-Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F.

Guang Yang

34B #8113-Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.

Herve Avet-Loiseau

34C #8114-Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

Steven P. Treon

35A #8115-Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma.

Adam J Waxman

35B #8116-Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols.

Bijay P. Nair

35C #8117-Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.

Christoph Johann Heuck

35D #8118-BIK (Bcl2-Interacting Killer) CpG methylation status as a potential predictive biomarker of relapsed/refractory multiple myeloma disease.

Eleftheria Hatzimichael

35E #8119-Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM).

John Crowley

35F #8120-Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.

Antje Hoering

35G #8121-Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).

Frits Van Rhee

35H #8122-Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk.

Jeffrey Sawyer

36A #8123-Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of m-CA for survival in total therapy protocols (TT1, TT2, TT3).

Jeff Haessler

36B #8124-Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma: Potential relevance to pharmacological use of erythropoietin.

Pamela S Becker

36C #8125-Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.

Shaji K Kumar, MD

36D #8126-Gene expression profiling (GEP) analysis of CD138-purified plasma cells (PC) obtained from MRI-defined focal lesions (FL) under CT guidance: Applying the 70 gene risk model and comparison with data generated on random samples (RS) from multiple myeloma (MM) treated with total therapy 2, 3, 4 and 5 (TT2, TT3, TT4 and TT5).

Ya-wei Qiang

36E #8127-Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies.

Daniel I Da Graca

36F #8128-Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

Ashraf Z. Badros

36G #8129-Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study.

Murielle Roussel

36H #8130-MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials.

Anders Waage

37A #8131-A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM).

Meaghan L Khan

37B #8132-Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).

Jatin J. Shah

37C #8133^ -Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

Sundar Jagannath

37D #8134-A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).

James R. Berenson, MD

37E #8135-Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).

Jeffrey Lee Wolf

37F #8136-The Arkansas experience with autotransplantation (AT) for older

37G #8137-Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study.

Andreas Guenther

37H #8138-Predicting 10+ year survivors in total therapy 1 (TT1) for multiple myeloma (MM).

Sarah Waheed

38A #8139-A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.

Don M. Benson

38B #8140-Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.

Noopur S. Raje, MD

38C #8141-Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.

Saad Usmani

38D #8142-Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)?

Chatchada Karanes, MD

38E #8143-A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.

Andrew Spencer

38F #8144-An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.

Tomer Martin Mark

38G #8145-Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis.

Massimo Vincenzo Martino

38H #8146-Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)?

Joanne Willey

39A #8147-Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.

Peter Lee

39B #8148-Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma.

Brian M Elliott

39F #8149-Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.

Muthu Veeraputhiran

39G #8150-Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.

Karim Belhadj

39H #8151-Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression.

Simon James Harrison

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #160: Lymphoma

Session Type: Oral Abstract Session

Date: Saturday, June 5

Location: E354a

Time: 1:00 PM - 4:00 PM

- Lymphoma

John Leonard, MD

- Lymphoma

Kenneth Stuart Cohen, MD

- #8004-Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.

Gilles A. Salles

- #8005-Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

Ruth Pettengell

- Discussion: Role of maintenance therapy in follicular lymphoma

Richard I. Fisher, MD

- #8006-Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD.

Francesca Fiore

- #8007-Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT).

Anna Sureda

- Discussion: Improving outcomes in Hodgkin Lymphoma

Ralph M. Meyer, MD

- #8008-Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The g-PCNSL-SG1 randomized phase IV trial.

Eckhard Thiel

- #8009-Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm).

Belinda A Campbell

- Discussion: What is the role of radiation in large cell lymphoma?

Joachim Yahalom, MD

- #8010-A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma.

Frédérique Kuhnowski

- #8011-Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study.

Taoufik EL Gnaoui

- #8012-Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

Ranjana Advani

Session Title: #223: Novel Therapies for Myeloma

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: E354a

Time: 4:30 PM - 6:00 PM

- Novel Therapies for Myeloma

Shaji K Kumar, MD

- Novel Therapies for Myeloma

Asher Alban Akmal Chanan-Khan, MD

- #8000-Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Ravi Vij

- #8001-Phase I/II study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

Jesús San-Miguel, MD, PhD

- Discussion: Novel proteasome and HDAC inhibitors in myeloma

Paul Gerard Guy Richardson, MD

- #8002-Pomalidomide plus dexamethasone (Pom/dex) is active in dual lenalidomide/bortezomib refractory multiple myeloma (MM).

Martha Lacy

- #8003-Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase 1 study.

Andrzej J. Jakubowiak, MD, PhD

- Discussion: New immunomodulatory agents and antibodies in myeloma

Sagar Lonial, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #130: Immunosuppression in Patients with Lymphoma and Myeloma

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 8:00 AM - 9:15 AM

- Prolonged B-cell Suppression from anti-CD20 therapies: What are the risks?

Myron Stefan Czuczman, MD

- Impact of T-cell Directed Therapies on Immunocompetence

Francine M. Foss, MD

- Prevention, Surveillance and Management of Viral Reactivation in the setting of Immunosuppressive Therapies for Lymphoma and Myeloma

John A. Zaia, MD

Session Title: #161: Myeloma

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E354b

Time: 9:30 AM - 12:30 PM

- Myeloma

Andrzej J. Jakubowiak, MD, PhD

- Myeloma

Todd M. Zimmerman, MD

- #8013-Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients.

Mario Boccardo

- #8014-Comparison of reduced-dose bortezomib plus thalidomide and dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.

Philippe Moreau

- Discussion: Sorting through the options for initial therapy of myeloma

Ruben Niesvizky, MD

- #8015- A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (MEL200) in newly diagnosed myeloma patients.

Antonio Palumbo, MD

- #8016-Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

Kenneth Carl Anderson

- Discussion: What is the role of transplant for myeloma in the era of novel agents?

Jean L. Harousseau, MD

- #8017-Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

Philip L. McCarthy, Bsc, MD

- #8018-Lenalidomide maintenance after transplantation for myeloma.

Michel Attal

- #8019-Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC).

Bart Barlogie

- #8020-Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

Sagar Lonial, MD

- #8021-Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX Study.

Gareth Morgan, PhD, FRCP

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III
Kathy Miller, MD
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy
Kathy Miller, MD
- Discussion: Lung Cancer - Metastatic
Charles M. Rudin, MD, PhD
- Discussion: Sarcoma
Gary K. Schwartz, MD
- Discussion: Gastrointestinal (Noncolorectal) Cancer
C. D. Blanke, MD
- Discussion: Head and Neck Cancer
Everett E. Vokes, MD